Evoke Pharma, Inc.

NasdaqCM:EVOK Stock Report

Market Cap: US$7.5m

Evoke Pharma Management

Management criteria checks 2/4

Evoke Pharma's CEO is Matt D'Onofrio, appointed in Mar 2024, has a tenure of 1.17 years. total yearly compensation is $1.27M, comprised of 48.3% salary and 51.7% bonuses, including company stock and options. directly owns 0.49% of the company’s shares, worth $36.33K. The average tenure of the management team and the board of directors is 3 years and 11 years respectively.

Key information

Matt D'Onofrio

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage48.34%
CEO tenure1.2yrs
CEO ownership0.5%
Management average tenure3yrs
Board average tenure11yrs

Recent management updates

Recent updates

Market Cool On Evoke Pharma, Inc.'s (NASDAQ:EVOK) Revenues Pushing Shares 29% Lower

Mar 16
Market Cool On Evoke Pharma, Inc.'s (NASDAQ:EVOK) Revenues Pushing Shares 29% Lower

Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely

Jan 22
Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely

Evoke to get US patent for nasal spray Gimoti

Sep 20

Evoke Pharma Q2 GAAP loss per share narrows, revenue up

Aug 10

Evoke Pharma gets Canadian patent linked to Gimoti nasal spray

Jul 06

Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?

Oct 22
Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?

Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?

Jul 06
Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?

CEO Compensation Analysis

How has Matt D'Onofrio's remuneration changed compared to Evoke Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$5m

Dec 31 2024US$1mUS$615k

-US$5m

Sep 30 2024n/an/a

-US$6m

Jun 30 2024n/an/a

-US$7m

Mar 31 2024n/an/a

-US$7m

Dec 31 2023US$857kUS$450k

-US$8m

Sep 30 2023n/an/a

-US$8m

Jun 30 2023n/an/a

-US$8m

Mar 31 2023n/an/a

-US$8m

Dec 31 2022US$602kUS$417k

-US$8m

Sep 30 2022n/an/a

-US$8m

Jun 30 2022n/an/a

-US$8m

Mar 31 2022n/an/a

-US$8m

Dec 31 2021US$1mUS$407k

-US$9m

Sep 30 2021n/an/a

-US$9m

Jun 30 2021n/an/a

-US$9m

Mar 31 2021n/an/a

-US$14m

Dec 31 2020US$828kUS$387k

-US$13m

Sep 30 2020n/an/a

-US$12m

Jun 30 2020n/an/a

-US$12m

Mar 31 2020n/an/a

-US$7m

Dec 31 2019US$852kUS$372k

-US$7m

Sep 30 2019n/an/a

-US$7m

Jun 30 2019n/an/a

-US$7m

Mar 31 2019n/an/a

-US$8m

Dec 31 2018US$831kUS$357k

-US$8m

Compensation vs Market: Matt's total compensation ($USD1.27M) is above average for companies of similar size in the US market ($USD645.80K).

Compensation vs Earnings: Matt's compensation has increased whilst the company is unprofitable.

CEO

Matt D'Onofrio (54 yo)

1.2yrs
Tenure
US$1,272,363
Compensation

Mr. Matthew J. D'Onofrio, also known as Matt, MBA, had been the Chief Business Officer and Executive Vice President at Evoke Pharma, Inc. since 2010 until 2023. He served as Treasurer and Secretary since M...

Leadership Team

NamePositionTenureCompensationOwnership
Matthew D'Onofrio
Co-Founder1.2yrsUS$1.27m0.49%
$ 36.3k
Mark Kowieski
CFO, Treasurer & Secretary1yrUS$670.24k0.24%
$ 18.2k
Marilyn Carlson
Chief Medical Officer11.4yrsUS$704.93k0.018%
$ 1.3k
Christopher Quesenberry
Chief Commercial Officer - Gimoti (TM)4.8yrsno datano data
3.0yrs
Average Tenure
54yo
Average Age

Experienced Management: EVOK's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Matthew D'Onofrio
Co-Founder1.2yrsUS$1.27m0.49%
$ 36.3k
Kenneth Widder
Independent Director17.9yrsUS$5.24k0%
$ 0
Todd Brady
Independent Director17.9yrsUS$5.37k0.0013%
$ 100.2
Cam Garner
Independent Chairman of the Board17.9yrsUS$6.53k0.12%
$ 8.6k
Malcolm Hill
Independent Director17.9yrsUS$5.37k0.0066%
$ 492.1
Vickie Reed
Independent Director4yrsUS$5.52k0%
$ 0
Benjamin Smeal
Independent Directorless than a yearUS$26.57kno data
Greg Pyszczymuka
Independent Directorless than a yearno datano data
11.0yrs
Average Tenure
58yo
Average Age

Experienced Board: EVOK's board of directors are seasoned and experienced ( 11 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/23 23:53
End of Day Share Price 2025/05/23 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Evoke Pharma, Inc. is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Difei YangBrean Capital
David BuckB. Riley Securities, Inc.